CINECA IRIS Institutional Research Information System

ALBERA, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.890
EU - Europa 3.632
AS - Asia 2.273
SA - Sud America 213
OC - Oceania 165
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 9
Totale 12.219
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.649
CN - Cina 1.001
IT - Italia 815
GB - Regno Unito 488
IE - Irlanda 414
FR - Francia 357
SG - Singapore 321
SE - Svezia 315
DE - Germania 265
FI - Finlandia 228
CA - Canada 205
JP - Giappone 195
KR - Corea 169
UA - Ucraina 158
BR - Brasile 139
AU - Australia 134
IN - India 130
TR - Turchia 107
VN - Vietnam 107
ES - Italia 98
NL - Olanda 84
PL - Polonia 66
BE - Belgio 64
ID - Indonesia 58
PT - Portogallo 48
CH - Svizzera 40
HK - Hong Kong 37
TW - Taiwan 37
AT - Austria 35
NZ - Nuova Zelanda 29
DK - Danimarca 28
MX - Messico 28
RU - Federazione Russa 25
PK - Pakistan 22
RO - Romania 21
CO - Colombia 19
AR - Argentina 18
CL - Cile 18
GR - Grecia 17
IL - Israele 17
TH - Thailandia 17
MY - Malesia 16
NO - Norvegia 14
PE - Perù 13
HU - Ungheria 12
IR - Iran 11
ZA - Sudafrica 11
PH - Filippine 10
EU - Europa 9
EG - Egitto 7
LT - Lituania 7
CZ - Repubblica Ceca 6
BG - Bulgaria 5
BY - Bielorussia 5
HR - Croazia 5
PR - Porto Rico 5
TN - Tunisia 5
MU - Mauritius 4
SA - Arabia Saudita 4
SK - Slovacchia (Repubblica Slovacca) 4
BD - Bangladesh 3
LB - Libano 3
LU - Lussemburgo 3
UY - Uruguay 3
CI - Costa d'Avorio 2
CR - Costa Rica 2
EC - Ecuador 2
FJ - Figi 2
LV - Lettonia 2
MN - Mongolia 2
SI - Slovenia 2
DZ - Algeria 1
GH - Ghana 1
GT - Guatemala 1
IQ - Iraq 1
LK - Sri Lanka 1
MA - Marocco 1
MT - Malta 1
NP - Nepal 1
OM - Oman 1
PY - Paraguay 1
QA - Qatar 1
RE - Reunion 1
RW - Ruanda 1
SC - Seychelles 1
SN - Senegal 1
UG - Uganda 1
UZ - Uzbekistan 1
Totale 12.219
Salva come PNG Salva come JPEG
Città #
Houston 958
Beijing 490
Chandler 416
Dublin 393
Fairfield 286
Santa Clara 270
Singapore 254
Ashburn 211
Hangzhou 190
Redwood City 188
Wilmington 172
Seattle 136
Villeurbanne 134
Woodbridge 130
Medford 128
Ann Arbor 123
Torino 123
Princeton 114
Columbus 103
Cambridge 90
Pisa 84
Milan 78
Jacksonville 77
Nyköping 74
Dong Ket 71
Dearborn 62
Turin 61
Duncan 57
London 56
Tokyo 56
Warsaw 55
Boston 51
Jakarta 48
Shanghai 47
Boardman 35
Ottawa 30
Toronto 30
New York 29
Washington 27
Istanbul 26
Los Angeles 26
Paris 25
Vienna 24
Guangzhou 22
Norwalk 22
Verona 22
Seoul 21
Lachine 20
San Diego 20
Ankara 19
Mumbai 19
Sydney 19
Brussels 18
Helsinki 18
Nanjing 17
São Paulo 17
Taipei 17
Madrid 16
Southend 16
Menlo Park 15
Mountain View 15
Phoenix 15
Santiago 15
Delhi 14
Québec 14
Barcelona 13
Beauharnois 13
Bengaluru 13
Lima 13
Rome 13
Rotterdam 13
Seongnam 13
Auckland 12
Chengdu 12
Chicago 12
Frankfurt am Main 12
Hefei 12
Hobart 12
Talavera de la Reina 12
Falls Church 11
Fremont 11
Hong Kong 11
New Delhi 11
San Jose 11
Silver Spring 11
Atlanta 10
Bangkok 10
Dallas 10
Denver 10
Nutley 10
Pittsburgh 10
Zurich 10
Detroit 9
Izmir 9
Mannheim 9
Porto 9
Stockholm 9
Athens 8
Auburn Hills 8
Berlin 8
Totale 6.809
Salva come PNG Salva come JPEG
Nome #
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. 2.730
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. 914
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. 601
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. 506
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. 388
Documento AIPO-SIMeR sulla fibrosi polmonare idiopatica 272
Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning. 259
Activated and memory alveolar T-lymphocytes in idiopathic eosinophilic pneumonia. 188
Relationship between circulating immune complexes, serum interferon and clinical features in sarcoidosis. 173
Eosinophils in eosinophilic pneumonia. 145
Evaluation of a novel tuberculosis complex-specific 34 kDa protein in the serological diagnosis of tuberculosis. 143
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial 141
Tachykinin activation of human monocytes from patients with interstitial lung disease, healthy smokers or healthy volunteers. 135
Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer. 133
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. 119
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points 117
Human renal angiomyolipoma cells of male and female origin can migrate and are influnced by microenvironmental factors 114
Risultati iniziali e prospettive future del Registro Piemontese delle Cardiopatie Congenite dell'Adulto 113
Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier 112
Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report. 111
Tachykinin activation of human alveolar macrophages in tobacco-smoke and in sarcoidosis: a phenotypical and functional study 110
The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report 105
Adenosine deaminase activity and fibronectin levels in bronchoalveolar lavage fluid in sarcoidosis and tuberculosis. 103
null 96
Awake or intubated surgery in diagnosis of interstitial lung diseases? A prospective study 94
Tumor/Stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis 90
Clinical guidelines and indications for bronchoalveolar lavage (BAL): pulmonary malignancies. 90
The clinical use of BAL in patients with pulmonary infections. 89
Corso di malattie dell'apparato respiratorio 87
First report of the Italian register for diffuse infiltrative lung disorders(RIPID). 86
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial 86
Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice 86
Alveolar inflammation in pulmonary sarcoidosis: cells and mediators. 85
Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide. 84
Analysis of survival in lung transplantation: Simple diagnostic tests in a new "SELeCT" Score used as prognostic tool. Results from a single center cohort study 83
[Alveolar macrophage subpopulations and circulating monocytes. Immunophenotypic study in healthy non-smokers] 82
Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality? 82
Three-dimensional demonstration of systemic blood supply to normal left basal segments 81
[Evaluation of leukocyte migration inhibition (LIF) in patients with carcinoma of the lung before and after the use of levamisole in vitro] 77
[Diagnosis of tuberculosis today] 77
Fibronectin levels in bronchoalveolar lavage fluid: a possible marker of sarcoidosis activity. 77
Combination chemotherapy for non small cell lung cancer stage III M0-1 with cisplatin and vinblastine in a divided-dose schedule. 76
Assessment of Phasic Changes of Vascular Size by Automated Edge Tracking-State of the Art and Clinical Perspectives 76
[In vitro lymphocyte immunoreactivity in sarcoidosis patients. Stimulation with Kveim antigens] 74
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) 74
Lymphocyte subpopulations analysis in pleural fluid and peripheral blood in patients with lymphocytic pleural effusions. 73
[Sarcoidosis] 71
First rigid bronchoscopy in COVID-19 pneumonia to treat a rare endobronchial tumor during extracorporeal membrane oxygenation 71
Mediastinal pulmonary sarcoidosis: clinical study of 87 cases 69
Alveolar immune mediators in HIV-related pneumonia. Different role of IL-2 and IL-1 in inducing lung damage. 68
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center 68
Sarcoid activity markers. 64
Alveolar and circulating CD8+ lymphocyte subsets in pulmonary sarcoidosis 64
Broncholaveolar Lavage in Sarcoidosis 63
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. 63
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials 63
Evaluation of immunomodulating effects of inhaled bacterial polyribosomal-Klebsiella pneumoniae proteoglycans complex on bronchoalveolar immune system in chronic bronchitis. 62
6-minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis (IPF): Confirmation of the minimal clinically important difference (MCID) 61
Fibrosi Polmonare 58
Validation of a Simple, Rapid, and Cost-Effective Method for Acute Rejection Monitoring in Lung Transplant Recipients 57
Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study. 57
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. 57
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. 57
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP) 54
Uno studio placebo-controllo sull’uso dell’interferon gamma-1b in pazienti con fibrosi polmonare idiopatica Commento editoriale da N Engl J Med 2004;350:125-33 A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis RAGHU G, BROWN KK, BRADFORD WZ, STARKO K, NOBLE PW, SCHWARTZ DA, KING TE FOR THE IDIOPATHIC PULMONARY FIBROSIS STUDY GROUP 54
SARS-CoV-2 Detection on Bronchoalveolar Lavage: An Italian Multicenter experience 54
Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis 53
Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1. 53
Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes 52
Think before: a guide to early diagnosis of pulmonary hypertension in patients with connective tissue diseases and vice versa. 51
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. 51
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. 51
Building bridges for innovation in ageing: Synergies between Action Groups of the EIP on AHA 50
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. 48
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis 48
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. 47
Progressive fibrosing interstitial lung diseases: A current perspective 47
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications 46
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials 46
Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. 43
COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy 41
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials 41
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good 41
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) 40
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 40
Riociguat for the treatment of pulmonary arterial hypertension. 40
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 40
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study. 40
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial 39
Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85) 37
Where do we stand with IPF treatment? 36
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial 36
Repopulation of human pulmonary epithelium by bone marrow cells: a potential means to promote repair 36
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis 35
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement 35
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis 34
Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics. 34
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study 34
Circulating biomarkers in pulmonary arterial hypertension: update and future direction. 34
Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience 32
Totale 12.303
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.016
article - articoli 0
book - libri 0
conference - conferenze 948
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.964
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020773 0 0 0 0 0 0 186 118 145 131 122 71
2020/20211.363 103 66 124 93 108 109 100 93 150 103 105 209
2021/20221.360 85 89 100 103 80 70 67 103 83 97 225 258
2022/20231.808 163 100 64 168 197 436 185 107 166 39 99 84
2023/20241.082 118 144 85 63 85 98 57 80 22 91 101 138
2024/20251.099 50 115 114 237 438 143 2 0 0 0 0 0
Totale 12.734